X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The achievement includes the successful synthesis of multiple tryptamine derivatives in sufficient quantities, drug ADME/PK has been completed and to demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the metabolism of a psychedelic tryptamine.
Lead Product(s): Tryptamine derivatives
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Cybin
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Agreement January 11, 2021
Details:
Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. -Adelia leadership bring extensive clinical and commercialization experience of major drugs, including Allegra, Sabril, Anzemet , and Vaniqa.
Lead Product(s): Fexofenadine Hydrochloride
Therapeutic Area: Immunology Product Name: Allegra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CYBIN
Deal Size: $15.75 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 14, 2020
Details:
Adelia’s leadership team brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science.
Lead Product(s): Ketamine analogs
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: CYBIN
Deal Size: $15.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
